The team is based in Austria and participates in UCI Continental Circuits races.

In July 2017, it was announced by the UCI that Matija Kvasina had tested positive for an experimental drug known as Molidustat (BAY-85-3934), during two tests taken during the 2017 Flèche du Sud – a race in which he won.

Molidustat represents a class of drugs that act on the same physiological pathways and enzyme cascades as those which are activated during altitude training.

Oxygen deprivation has the effect of stimulating the body's production of erythropoietin (EPO) – Molidustat imitates this.

[1][2] Kvasina was subsequently kicked out of the 2017 Tour of Austria.